Dark

CYDY
CYTODYN INC
stock OTC

EOD

Aug 5, 2026

0.1870USD-0.362%(-0.0007)1,624,891

Pre-market

0.00USD-100.000%(-0.19)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 25, 2022

06:06PM EST CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab Business Wire

Jan 13, 2022

09:00AM EST CytoDyn Cancels Webcast and Live Q/A Scheduled for Today Business Wire

Jan 11, 2022

04:36PM EST CytoDyn to Hold Webcast and Live Q/A on January 13 GlobeNewswire Inc

Jan 10, 2022

09:01AM EST Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV PR Newswire

08:05AM EST CytoDyn Highlights Research Paper 'Leronlimab (PRO 140) activity against 4-class drug resistant HIV-1 from Heavily Treatment Experienced Subjects' In ScienceDirect Benzinga

08:00AM EST Published Paper Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced ("HTE") Subjects Business Wire

Jan 5, 2022

09:26AM EST Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1) for Per Protocol Population in 350 mg Weekly Dose Business Wire

Dec 22, 2021

08:43AM EST CytoDyn Announces Favorable Ruling Granting Injunction Against Former Contract Research Organization RTTNews

08:39AM EST CytoDyn Announces Favorable Ruling Granting Injunction Against Former CRO Business Wire

Dec 21, 2021

08:59AM EST CytoDyn Gets Positive Response From FDA On Phase 3 Trial In COVID-19 Critically Ill Population RTTNews

08:56AM EST CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population Business Wire

Dec 13, 2021

08:00AM EST NASH Phase 2 Trial Open-Label Portion Demonstrates Average 80 msec cT1 Reduction in 50% of Patients and Reduction of Nearly 50 msec in 80% of Patients Business Wire

Dec 10, 2021

04:00PM EST CytoDyn to Hold Webcast and Live Q/A on December 14 GlobeNewswire Inc

Dec 9, 2021

08:56AM EST CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population Business Wire

08:26AM EST CytoDyn Files for Expanded Access Use of Leronlimab for Multi-Drug Resistance HIV Patients Business Wire

Dec 8, 2021

08:44AM EST CytoDyn's CRO in Brazil Met with ANVISA to Modify CD16 Trial for Critically Ill COVID-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022 Business Wire

Dec 1, 2021

08:00AM EST CytoDyn Submits CMC (Manufacturing) Section of HIV BLA to FDA Under Previously Authorized Rolling Review; Last (Clinical) Section Will Complete Full BLA Submission Business Wire

Nov 29, 2021

04:27PM EST CytoDyn's Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at World Antiviral Congress 2021 Beginning Tomorrow Business Wire

Nov 24, 2021

04:01PM EST CytoDyn Announces Preliminary Results from 2021 Annual Meeting Business Wire

08:55AM EST Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst First 15 Patients with Average Reduction of 24 msec Business Wire

Nov 19, 2021

08:00AM EST CytoDyn Research Paper on Leronlimab Published in Frontiers in Immunology Journal Business Wire

Nov 16, 2021

04:00PM EST Health Canada Authorizes Emergency Use of Leronlimab for Treatment of First Triple-Negative Breast Cancer Patient in Canada Business Wire

02:00PM EST CytoDyn Reminds Stockholders to Register 24 hours before November GlobeNewswire Inc

06:00AM EST Second portion out of three major portions of BLA (CMC portion) will be submitted shortly GlobeNewswire Inc

Nov 8, 2021

06:00AM EST Ongoing analysis of data from 28 mTNBC patients following 12 months of treatment with leronlimab is very encouraging given little-to-no effective treatment options currently GlobeNewswire Inc

Nov 3, 2021

06:00AM EDT CytoDyn Reports Preliminary Results from First Five Patients in GlobeNewswire Inc

06:00AM EDT CytoDyn Announces Cancer Update: 12-month Analysis of 28 mTNBC GlobeNewswire Inc

Oct 28, 2021

11:08AM EDT CytoDyn Inc. Announces Adjournment of Annual Meeting of Shareholders to November 24, 2021 Due to Lack of Quorum Business Wire

Oct 26, 2021

07:00AM EDT EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 19th Emerging Growth Conference. GlobeNewswire Inc

Oct 25, 2021

06:13AM EDT CytoDyn Announces Treatment Of First Patient In Phase 3 Trial For COVID-19 Patients In Brazil RTTNews

06:00AM EDT Based on previous strong sub-population analysis in CD12 trial, CytoDyn intends to file for an EUA when interim analysis of 127 patients is completed GlobeNewswire Inc

Oct 21, 2021

06:00AM EDT CytoDyn to Hold Webcast and Live Q/A on October 26 GlobeNewswire Inc

Oct 20, 2021

04:27PM EDT CytoDyn Announces Delaware Court Has Denied Activist Group's Motion to Prevent Annual Meeting from Taking Place Business Wire

Oct 18, 2021

07:01AM EDT CytoDyn Alerts Shareholders to Vote on Company's Proxy Card Ahead of October 28th Annual Meeting Business Wire

Oct 14, 2021

11:38AM EDT Group of CytoDyn Stockholders Comments on Delaware Court Decision Business Wire

07:00AM EDT Delaware Court Agrees with CytoDyn that Activist Group's Nominations are Invalid Business Wire

Oct 12, 2021

08:49AM EDT These OTC Markets Securities had the Most Trading Activity in September Benzinga

07:00AM EDT EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets, announces the Schedule of the 18th Emerging Growth Conference. GlobeNewswire Inc

Oct 7, 2021

02:27PM EDT CytoDyn to Present at Emerging Growth Conference on October 13 GlobeNewswire Inc

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

06:02AM EDT Clinical Trial Development Targeting Triple-Negative Breast Cancer (TNBC) to Evaluate Anti-Tumor Effects and Identify Immunological Biomarkers for Leronlimab in Combination with Immune Checkpoint Blockade GlobeNewswire Inc

06:01AM EDT New hires in Bioanalytical Sciences, Biostatistics, Clinical Regulatory, and Clinical Project Management will join the team of Drs. Srinivasan, Recknor, Ray, and Kelly to lead all clinical trials with new CROs GlobeNewswire Inc

06:00AM EDT All clinical activities have been moved away from Amarex; a complete update on all activities will be provided to shareholders next week by Drs. Recknor, Kelly, Ray, and Pourhassan GlobeNewswire Inc

Sep 29, 2021

12:57PM EDT CytoDyn Comments on Rosenbaum/Patterson Activist Group "Plan" Business Wire

Sep 28, 2021

Sep 27, 2021

06:30PM EDT Group of CytoDyn Stockholders Releases White Paper Regarding Company's Extremely Unfavorable Borrowing Practices Business Wire

12:34PM EDT CytoDyn to Present at Emerging Growth Conference on September 29 Followed by Live Q/A Business Wire

Sep 24, 2021

08:00AM EDT Group of CytoDyn Stockholders Shares Strategic Plan to Obtain Cancer Therapy Approval for Leronlimab Business Wire

Sep 22, 2021

08:05AM EDT CytoDyn Says Brazil's FDA OKs To Begin Phase 3 Trial In COVID-19 Patients With IV Administration Of 4 Doses RTTNews

08:00AM EDT CytoDyn Receives Clearance from Brazil's FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg/week) Business Wire

Sep 21, 2021

08:00AM EDT CytoDyn's Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at the World Antiviral Congress 2021 Business Wire

Sep 20, 2021

11:05AM EDT Group Of CytoDyn Stockholders Announces Federal Court Dismisses Litigation Brought By Company RTTNews

10:18AM EDT CytoDyn Announces Resolution of Federal Litigation with Rosenbaum/Patterson Activist Group Business Wire

Sep 17, 2021

08:00AM EDT Bruce Patterson, M.D., Director Candidate for CytoDyn Board, Presents at International COVID Summit Business Wire

Sep 14, 2021

Sep 13, 2021

06:00AM EDT CytoDyn to Present at Emerging Growth Conference on September 15 GlobeNewswire Inc

Sep 10, 2021

08:00AM EDT The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test Benzinga

Sep 9, 2021

08:30PM EDT An interim analysis will be conducted 28 days following enrollment of 245 patients (40% of targeted trial patients) GlobeNewswire Inc

Sep 7, 2021

08:30AM EDT Group of CytoDyn Stockolders Responds to Misleading Company News Release Business Wire

Sep 2, 2021

06:40PM EDT CytoDyn to Hold Webcast on September 8 to Discuss Results from GlobeNewswire Inc

05:32PM EDT CytoDyn Highlights Court Ordering Rosenbaum/Patterson Group to Comply With the Federal Securities Laws Business Wire

08:30AM EDT Group of CytoDyn Stockholders Warns Stockholders of Board's Continued Value Destruction and Failures Business Wire

Aug 26, 2021

05:03PM EDT Dr. Srinivasan provides 30 years of broad regulatory and drug development experienceincluding a career serving as Director of CMC Regulatory Affairs for Regeneron Pharmaceuticals, Inc. where he led the CMC strategy and successfully submitted a monoclonal antibody based BLA (Dupixent approved in 2017) GlobeNewswire Inc

08:30AM EDT Group of CytoDyn Stockholders Files Lawsuit to Force Company to Allow Stockholders to Vote for Alternative Director Nominees Business Wire

Aug 25, 2021

08:42AM EDT CytoDyn Urges Shareholders To Ignore Proxy Cards From Rosenbaum/Patterson RTTNews

08:34AM EDT CytoDyn Urges Shareholders to Ignore Proxy Cards from Rosenbaum/Patterson Group Business Wire

08:00AM EDT Decreases in Circulating Tumor Cells after leronlimab induction were seen in 73% of the patients and associated with increase in PFS and OS GlobeNewswire Inc

Aug 19, 2021

03:51PM EDT Group of CytoDyn Stockholders Responds to Highly Misleading Company Release Business Wire

08:10AM EDT CytoDyn Updates On Rosenbaum/Patterson Group Litigation RTTNews

08:00AM EDT CytoDyn Provides Update on Rosenbaum/Patterson Group Litigation Business Wire

Aug 13, 2021

06:14AM EDT CytoDyn Receives FDA Guidance For HIV BLA Dose Justification Report RTTNews

06:00AM EDT Company Believes All Issues Are Addressable and it Will Be Able to Continue BLA Resubmission GlobeNewswire Inc

Aug 5, 2021

09:26AM EDT CytoDyn Files Lawsuit Against Rosenbaum/Patterson Activist Group for Misleading Shareholders and Waging an Unlawful Proxy Contest Business Wire

Aug 3, 2021

06:00AM EDT CytoDyn Receives Clearance from Brazil's ANVISA to Commence Phase 3 Trial for Severe COVID-19 Patients Business Wire

Aug 2, 2021

07:00AM EDT CytoDyn Announces That Director Nominations by Rosenbaum/Patterson Activist Group Are Invalid Business Wire

Jul 28, 2021

12:05PM EDT OTC Markets Hits Major Milestones in Mid-Year Along With Big Volume and Gaining Securities Benzinga

Jul 19, 2021

04:41PM EDT CytoDyn to Hold Webcast on July 22 to Discuss Results from Cancer GlobeNewswire Inc

06:22AM EDT CytoDyn Announces Preliminary Results From 30 MTNBC Patients Treated With Leronlimab RTTNews

06:00AM EDT CytoDyn Announces Preliminary Results from 30 mTNBC Patients GlobeNewswire Inc

Jul 12, 2021

06:00AM EDT CytoDyn anticipates preliminary efficacy data regarding potential responders in metastatic triple-negative breast cancer in approximately two weeks GlobeNewswire Inc

Jul 6, 2021

06:50AM EDT CytoDyn Inc. (CYDY) on Tuesday said its lead drug candiate, leronlimab, has been granted patent for methods of treating coronavirus infection by the U.S. Patent and Trademark Office (USPTO). RTTNews

06:10AM EDT CytoDyn Granted USPTO Patent For Methods Of Treating Coronavirus Infection With Leronlimab RTTNews

06:00AM EDT CytoDyn Granted a Significant Patent by USPTO for Methods of GlobeNewswire Inc

Jul 1, 2021

06:08PM EDT Management works to advance its BLA filing seeking FDA approval for leronlimab as a combination therapy for HIV patients while continuing its evaluation of other potential indications GlobeNewswire Inc

05:32PM EDT Group of Cytodyn Stockholders Nominates Five Highly Qualified Director Candidates to Replace Board Responsible for Mismanagement and Value Destruction Business Wire

Jun 21, 2021

08:30AM EDT CytoDyn Inc. (OTCQB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today preliminary results after unblinding the data from its COVID-19 long-haulers clinical trial. GlobeNewswire Inc

Jun 16, 2021

04:01PM EDT CytoDyn to Hold Webcast on June 21 to Discuss Unblinded Data from GlobeNewswire Inc

Jun 7, 2021

08:51AM EDT Leronlimab to be studied as potential HIV PrEP drug in humans through an early clinical trial GlobeNewswire Inc

Jun 1, 2021

09:26AM EDT CytoDyn: Chiral Pharma In The Philippines Places First Purchase Order For Leronlimab RTTNews

09:23AM EDT CytoDyn and Philippine Airlines Work Together to Provide Filipinos GlobeNewswire Inc

09:15AM EDT Chiral is simultaneously working on application for Emergency Use Authorization GlobeNewswire Inc

May 27, 2021

06:23AM EDT CytoDyn: Biomm Plans To Submit Authorization To Conduct Phase 3 Clinical Studies Of Leronlimab RTTNews

06:00AM EDT Biomm S.A. Announces Plans to Submit Authorization to Conduct GlobeNewswire Inc

May 20, 2021

04:55PM EDT Antonio Migliarese Promoted to Chief Financial Officer of CytoDyn GlobeNewswire Inc

May 18, 2021

08:48AM EDT CytoDyn Stock Falls After FDA Rebukes Claims On COVID-19 Treatment Benzinga

07:44AM EDT The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO Benzinga

06:07AM EDT CytoDyn Intends To Submit Results Of Newly Completed Topline Report Of CD12 Phase 3 Trial Data RTTNews

06:00AM EDT Finalized data analysis shows CD12 trial reached almost all of its major secondaryendpoints in a subpopulation (62 patients) of critically ill COVID-19 GlobeNewswire Inc

May 17, 2021

07:45PM EDT CytoDyn to Hold Webcast on May 18 to Discuss GlobeNewswire Inc

12:16AM EDT Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against CytoDyn, Inc. - CYDY PR Newswire

May 14, 2021

10:30PM EDT Pomerantz LLP is investigating claims on behalf of investors of CytoDyn Inc. (CytoDyn or the Company) (OTCMKTS:CYDY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

06:06PM EDT CYTODYN 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against CytoDyn, Inc. - CYDY Business Wire

11:11AM EDT The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Western District of Washington against CytoDyn Inc. (OTCMKTS: CYDY) (CytoDyn) on behalf of those who purchased or acquired CytoDyn common stock between March 27, 2020 and March 9, 2021, inclusive (the Class Period). GlobeNewswire Inc

May 13, 2021

05:53PM EDT Final Deadline Approaching on May 17, 2021: Kessler Topaz Meltzer & Check, LLP PR Newswire

08:56AM EDT Macleods is one of the largest pharmaceutical companies in India with presence in over 140 countries GlobeNewswire Inc

May 12, 2021

09:53PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

10:42AM EDT These OTC Securities Had the Most Trading Activity in April Benzinga

May 11, 2021

10:34PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

May 9, 2021

03:10PM EDT CYDY DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds GlobeNewswire Inc

May 8, 2021

04:46PM EDT Pomerantz LLP is investigating claims on behalf of investors of CytoDyn Inc. (CytoDyn or the Company) (OTCMKTS:CYDY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

12:47PM EDT Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against CytoDyn Inc. PR Newswire

May 7, 2021

10:35PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

06:00AM EDT Drs. Pourhassan, Recknor, Seethamraju and Nicolas will appear in a one-hour segment beginning at 5:00 pm PT / 8:00 pm ET, Sunday, May 9 GlobeNewswire Inc

May 6, 2021

May 5, 2021

03:35AM EDT Interim analysis for critically ill population will be conducted when enrollment reaches about 120 patients or 40% of the approximate 300 patients GlobeNewswire Inc

May 3, 2021

11:05PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

10:41AM EDT Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against CytoDyn Inc. (CYDY) PR Newswire

09:05AM EDT CytoDyn to Hold Webcast on May 5 to Provide Update on Multiple GlobeNewswire Inc

09:02AM EDT Data from 10 Patients with Stage Four Cancer Treated with GlobeNewswire Inc

09:00AM EDT Following the successful conclusion of three clinical trials, approximately 120 patients continue treatment with leronlimab in extension arms GlobeNewswire Inc

May 2, 2021

03:31PM EDT The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Western District of Washington against CytoDyn Inc. (OTCMKTS: CYDY) (CytoDyn) on behalf of those who purchased or acquired CytoDyn common stock between March 27, 2020 and March 9, 2021, inclusive (the Class Period). GlobeNewswire Inc

Apr 27, 2021

06:30PM EDT CYDY INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline PR Newswire

04:01PM EDT CytoDyns Chief Medical Officer Dr. Scott Kelly GlobeNewswire Inc

Apr 26, 2021

10:43PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Apr 24, 2021

08:39PM EDT Pomerantz LLP is investigating claims on behalf of investors of CytoDyn Inc. (CytoDyn or the Company) (OTCMKTS:CYDY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

03:21PM EDT Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities GlobeNewswire Inc

Apr 23, 2021

10:50PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Apr 21, 2021

05:25PM EDT Investor Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of PR Newswire

Apr 20, 2021

10:57PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

08:10PM EDT The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Western District of Washington against CytoDyn Inc. (OTCMKTS: CYDY) (CytoDyn) on behalf of those who purchased or acquired CytoDyn common stock between March 27, 2020 and March 9, 2021, inclusive (the Class Period). GlobeNewswire Inc

Apr 19, 2021

11:00PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

06:14AM EDT CytoDyn Submits CMC Of Application For Interim Order For COVID-19 Under Rolling Review RTTNews

06:05AM EDT Clinical trial in U.S. for critically ill COVID-19 patients expected to initiate soon GlobeNewswire Inc

06:00AM EDT CytoDyn is following all patients treated with leronlimab under CSP and will provide additional information when available and authorized for release GlobeNewswire Inc

Apr 16, 2021

10:50PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

04:04PM EDT The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Western District of Washington against CytoDyn Inc. (OTCMKTS: CYDY) (CytoDyn) on behalf of those who purchased or acquired CytoDyn common stock between March 27, 2020 and March 9, 2021, inclusive (the Class Period). GlobeNewswire Inc

Apr 15, 2021

10:50PM EDT Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class PR Newswire

09:26AM EDT Under Compassionate Special Permit (CSP) in Philippines, CytoDyn is well positioned to generate significant revenues GlobeNewswire Inc

Apr 14, 2021

11:52PM EDT Pomerantz LLP is investigating claims on behalf of investors of CytoDyn Inc. (CytoDyn or the Company) (OTCMKTS:CYDY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

10:56PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Apr 13, 2021

11:00PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

08:47AM EDT Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating claims of violations of federal securities laws on behalf of investors of CytoDyn Inc. (CytoDyn or the Company) (OTCMKTS: CYDY). If you are a shareholder of CytoDyn with more than $300,000 in losses, you should contact the Firm. GlobeNewswire Inc

Apr 12, 2021

10:57PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

11:27AM EDT SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Announces GlobeNewswire Inc

Apr 10, 2021

12:28PM EDT Securities Fraud Class Action Lawsuit was filed on Behalf of Investors of CytoDyn Inc. PR Newswire

Apr 9, 2021

10:45PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Apr 8, 2021

06:01PM EDT CYDY Reminder: Kessler Topaz Meltzer & Check, LLP - Deadline GlobeNewswire Inc

05:42PM EDT CytoDyns COVID-19 Long-Haulers GlobeNewswire Inc

08:39AM EDT Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating claims of violations of federal securities laws on behalf of investors of CytoDyn Inc. (CytoDyn or the Company) (OTCMKTS: CYDY). GlobeNewswire Inc

Apr 7, 2021

04:01PM EDT CytoDyn also negotiating the potential future delivery of 100,000 vials to the Philippines for additional CSP use GlobeNewswire Inc

06:00AM EDT CytoDyn Signs Exclusive Supply and Distribution Agreement with GlobeNewswire Inc

Apr 6, 2021

10:47PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

Apr 5, 2021

10:57PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

04:29PM EDT CytoDyn Reschedules Webcast from April 6 to April 7 GlobeNewswire Inc

10:11AM EDT CytoDyn Inc. Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of PR Newswire

06:26AM EDT CytoDyn Completes An Additional Potentially Non-dilutive Convertible Debt Offering RTTNews

06:05AM EDT CytoDyn Completes $28.5 Million Convertible Note Financing with GlobeNewswire Inc

06:00AM EDT First Compassionate Special Permit (CSP) Patient in Philippines GlobeNewswire Inc

Apr 4, 2021

05:10PM EDT Important Investor Reminder: Kessler Topaz Meltzer & Check, LLP GlobeNewswire Inc

Apr 2, 2021

Apr 1, 2021

06:15AM EDT CytoDyn to Hold Webcast on April 6 to Provide a Full Update on Its GlobeNewswire Inc

06:05AM EDT CytoDyn Files New Protocol With FDA For 4 Doses Of Leronlimab For Critically Ill COVID-19 Patients RTTNews

06:00AM EDT Trial commencement will be expedited by enrolling patients in Brazil, U.K., and Canada while immediate EUA requests are pursued in multiple countries GlobeNewswire Inc

Mar 31, 2021

10:50PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

01:46PM EDT CYDY Reminder: Kessler Topaz Meltzer & Check, LLP - Deadline GlobeNewswire Inc

Mar 30, 2021

07:37PM EDT Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for CytoDyn PR Newswire

06:00AM EDT Clinical outcome improvement (based on ordinal scale) with leronlimab at day 14 was 400% better than placebo arm with p-value of 0.021 GlobeNewswire Inc

Mar 29, 2021

11:05PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

06:15AM EDT CD12 trial results also indicated that five out of six patients on ECMO recovered GlobeNewswire Inc

06:00AM EDT CytoDyn is simultaneously pursuing EUA in the Philippines while expanding its access under CSP GlobeNewswire Inc

Mar 27, 2021

11:40AM EDT Investor Alert: Kessler Topaz Meltzer & Check, LLP Reminds GlobeNewswire Inc

Mar 26, 2021

10:50PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Mar 25, 2021

02:11PM EDT Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class PR Newswire

Mar 24, 2021

10:51PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Mar 23, 2021

10:51PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

07:47PM EDT CYDY ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors GlobeNewswire Inc

Mar 22, 2021

10:50PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Mar 20, 2021

03:33PM EDT CYDY Class Action Alert: Kessler Topaz Meltzer & Check, LLP Announces a PR Newswire

Mar 19, 2021

07:07PM EDT The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Western District of Washington against CytoDyn Inc. (OTCMKTS: CYDY) (CytoDyn) on behalf of those who purchased or acquired CytoDyn common stock between March 27, 2020 and March 9, 2021, inclusive (the Class Period). GlobeNewswire Inc

03:14PM EDT Gainey McKenna & Egleston Announces A ClassAction GlobeNewswire Inc

Mar 18, 2021

10:26AM EDT Scott+Scott Attorneys at Law LLP (Scott+Scott), an international securities and consumer rights litigation firm, today announced that it has filed a class action lawsuit against CytoDyn, Inc. (CytoDyn or the Company) and Chief Executive Officer Andy Heyward (collectively, Defendants). GlobeNewswire Inc

12:39AM EDT CytoDyn to Hold Webcast on March 22 to Provide an Update on GlobeNewswire Inc

Mar 17, 2021

08:41AM EDT Traders Demonstrate Enthusiasm For Emerging Sectors In February Benzinga

Mar 16, 2021

06:00AM EDT Dr. Recknor will continue to oversee the Company's COVID-19 long-haulers and Phase 2 NASH trials GlobeNewswire Inc

Mar 15, 2021

03:45PM EDT INVESTIGATION ALERT: Kessler Topaz Meltzer & Check, LLP is Investigating PR Newswire

Mar 11, 2021

03:35AM EST CytoDyns Long-Haulers COVID-19 Trial Enrolled 20 GlobeNewswire Inc

Mar 8, 2021

06:10AM EST These trial results are currently being prepared to be submitted for publication GlobeNewswire Inc

06:05AM EST U.S. FDA Reviewing Protocol for More COVID-19 Critical Patients to be Enrolled to Support Potential EUA GlobeNewswire Inc

06:00AM EST CytoDyns Phase 3 Trial Demonstrates Safety, a GlobeNewswire Inc

Mar 6, 2021

08:41PM EST U.S. FDA Reviewing Protocol for More COVID-19 Critical Patients to be Enrolled to Support Potential EUA GlobeNewswire Inc

Mar 5, 2021

06:30PM EST CytoDyn to Hold Webcast on March 8 to Provide Overview of CD12 GlobeNewswire Inc

05:47PM EST CytoDyns Phase 3 Trial Demonstrates Safety, a GlobeNewswire Inc

Mar 3, 2021

05:28PM EST CytoDyn Files Form S-3 to Replace Expiring Shelf Registration GlobeNewswire Inc

Feb 22, 2021

06:03AM EST CytoDyn Says CD12 COVID-19 Trial Data Has Been Unblinded RTTNews

06:00AM EST CytoDyn expects to release CD12 data and complete discussions with various regulatory agencies within 2 to 3 weeks GlobeNewswire Inc

Jan 29, 2021

04:01PM EST CytoDyn will dedicate at least 200,000 vials (100,000 doses) of leronlimab from its inventory to Chiral Pharma Corp. for potential sales in the Philippines GlobeNewswire Inc

Jan 25, 2021

09:35AM EST The Most Actively Traded Securities On OTC Markets In 2020 Included Cannabis, Crypto, And Multinationals Benzinga

Jan 4, 2021

06:00AM EST REMINDER: CytoDyn to Hold Webcast on January 6 to Provide GlobeNewswire Inc

Dec 31, 2020

01:06AM EST CytoDyn Publishes Research Manuscript On Critically Ill COVID-19 Patients In Journal Of Translational Autoimmunity RTTNews

12:49AM EST Manuscript entitled: Disruption of CCR5 Signaling to Treat COVID-19-Associated Cytokine Storm: Case Series of Four Critically Ill Patients Treated with Leronlimab, by Nicholas J. Agresti, M.D. GlobeNewswire Inc

Dec 30, 2020

11:39PM EST The agency also provided specific guidance for inclusion/exclusion criteria for patients seeking leronlimab under eIND authorization GlobeNewswire Inc

01:35AM EST CytoDyn to Hold Webcast on January 6 to Provide Timelines for GlobeNewswire Inc

Dec 25, 2020

01:52AM EST CytoDyn: FDA Provides Guidance For Adding Open-Label RTTNews

Dec 24, 2020

07:47PM EST The agency will also consider eINDs for patients in other hospitals who qualify for inclusion criteria similar to CD12 GlobeNewswire Inc

Dec 22, 2020

06:43AM EST CytoDyn Inc. (CYDY) said a treating physician has received authorization from the FDA to administer leronlimab for a COVID-19 patient under emergency IND. CytoDyn said FDA's decision will enable it to respond to ongoing requests for leronlimab until phase 3 trial data is unblinded. RTTNews

06:28AM EST CytoDyn: FDA Resumes EIND Approval For Severe-to-Critical COVID-19 Patients Use Of Vyrologix RTTNews

06:00AM EST FDAs decision will enable CytoDyn to respond to ongoing requests for leronlimab until Phase 3 trial data is unblinded GlobeNewswire Inc

Dec 15, 2020

04:01PM EST CytoDyn is simultaneously finalizing an EUA application with the Philippine FDA with patient data from CD10 and recent eINDs for severe-to-critical patients GlobeNewswire Inc

Dec 3, 2020

02:36PM EST CytoDyn to Hold Webcast on December 10 to Update Clinical and GlobeNewswire Inc

Dec 2, 2020

06:12AM EST CytoDyn: First Patient First Visit Metric Met For Phase 2 Trial For Nonalcoholic Steatohepatitis RTTNews

06:00AM EST Preclinical results demonstrated leronlimab effectively inhibited fatty liver development GlobeNewswire Inc

Nov 23, 2020

04:16PM EST Vyrologix (leronlimab) has successfully replicated the CCR5 deficient phenotype in a pre-clinical animal study, and will now initiate HIV cure-focused clinical studies in collaboration with amfAR GlobeNewswire Inc

06:00AM EST Concurrently,CytoDyn is workingdiligently with the FDA to initiateits Phase 2 COVID-19 Long Hauler Trial, with more than 100 volunteers wanting to enroll GlobeNewswire Inc

Nov 17, 2020

09:50AM EST CytoDyn Inc said it has filed a protocol with the U.S. Food and Drug Administration for a Phase 2 clinical trial for leronlimab as a treatment for COVID-19 patients suffering from long-hauler symptoms. RTTNews

09:11AM EST CytoDyn Files Protocol With FDA For Phase 2 Trial For COVID-19 Patients With Long-Hauler Symptoms RTTNews

09:00AM EST CytoDyn Files Protocol with U.S. FDA for Phase 2 Clinical Trial GlobeNewswire Inc

Nov 16, 2020

06:05AM EST CytoDyn Announces Registration of Trademark for VYROLOGIX in GlobeNewswire Inc

06:00AM EST Health Canada Clears CytoDyn to File its BLA for Leronlimab as One GlobeNewswire Inc

Nov 11, 2020

06:00AM EST CytoDyn Completes Second Non-dilutive $28.5 Million Convertible GlobeNewswire Inc

Nov 2, 2020

01:17PM EST CytoDyn to Hold Webcast on November 5 to Update Clinical and GlobeNewswire Inc

Oct 27, 2020

12:49AM EDT CytoDyn Says U.K. MHRA Clears CytoDyn To File BLA For Leronlimab As One Injection Per Week For Combination HIV Therapy RTTNews

Oct 26, 2020

06:00AM EDT CytoDyn Inc. (OTC.QB: CYDY), (CytoDyn or the Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today two patients have demonstrated noticeable signs of improvement following treatment with leronlimab (PRO 140) in helping their recovery from stroke. GlobeNewswire Inc

Oct 20, 2020

08:17AM EDT The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger Benzinga

06:12AM EDT CytoDyn Gets Positive DSMC Recommendation To Continue Study For Leronlimab RTTNews

06:00AM EDT DSMC recommendsCytoDyn continue the study as planned, with the protocol defined sample size and power to achieve the primary endpoint GlobeNewswire Inc

Oct 19, 2020

06:33PM EDT * * REVISED TIME * * CytoDyn to Hold Webcast on October 20 to GlobeNewswire Inc

Oct 15, 2020

11:00PM EDT CytoDyn to Hold Webcast on October 20 to Discuss GlobeNewswire Inc

Oct 12, 2020

08:12PM EDT CytoDyn Appoints Chiral Pharma to Secure Leronlimab for Local FDA GlobeNewswire Inc

Sep 29, 2020

04:12PM EDT CytoDyn to Hold 2020 Virtual Annual Meeting of Stockholders on GlobeNewswire Inc

Sep 23, 2020

12:53AM EDT CytoDyns Phase 2 Study of Leronlimab for GlobeNewswire Inc

Sep 20, 2020

09:14PM EDT CytoDyns CEO Dr. Pourhassan and CMO Dr. Kelly to GlobeNewswire Inc

Sep 10, 2020

04:50PM EDT CytoDyn to Hold Conference Call on September 16 to Provide Update GlobeNewswire Inc

Sep 2, 2020

04:01PM EDT U.S. FDA schedules Type A meeting with CytoDyn to discuss BLA filing for HIV GlobeNewswire Inc

Sep 1, 2020

06:00AM EDT Leading experts in the fields of HIV, Oncology, Rheumatology, and NASH join together to facilitate the best approaches to utilize multiple opportunities for leronlimab GlobeNewswire Inc

Aug 28, 2020

04:37PM EDT CytoDyn to Hold Conference Call on September 2 to Provide Update GlobeNewswire Inc

Aug 26, 2020

11:50AM EDT Senior Administration Official Says CytoDyn Isn't Being Considered For Operation Warp Speed At This Time Benzinga

Aug 25, 2020

08:48PM EDT Interim analysis to commence after 28 days; results anticipated by mid-October GlobeNewswire Inc

Aug 20, 2020

04:51AM EDT After Several Months of Providing Requested Information About GlobeNewswire Inc

03:36AM EDT To Avoid Delay, the FDA Recommends CytoDyn Conduct Its Type A GlobeNewswire Inc

Aug 19, 2020

02:57AM EDT CytoDyn Announces Upcoming Retirement Of David Welch From Its Board RTTNews

02:44AM EDT CytoDyn Announces Upcoming Retirement of Dr. David Welch from its GlobeNewswire Inc

01:25AM EDT CytoDyn Requests Fast Track GlobeNewswire Inc

Aug 17, 2020

12:55PM EDT These Were The Hottest Companies On OTC Markets In July Benzinga

06:15AM EDT HIV monotherapy trials update: 215 patients completed almost one year of monotherapy. Only some were allowed to continue in extension arm; five patients reached almost 6 years. Twenty-five reached 2 to 4 years and 20 patients are 1 to 2 years GlobeNewswire Inc

06:03AM EDT CytoDyn Submits Top-line Report From Phase 2 COVID-19 Trial To FDA RTTNews

06:00AM EDT The Top-line Report has been sent to the regulatory authorities in Mexico, and will be provided to U.K. MHRA, and E.U. EMA, with requests for emergency use approval GlobeNewswire Inc

Aug 11, 2020

03:41PM EDT CytoDyn to Hold Conference Call on August 12 to Discuss Impressive GlobeNewswire Inc

09:15AM EDT Primary endpoint shows early clinical improvement in symptom score at Day 3 in patients receiving leronlimab GlobeNewswire Inc

Jul 27, 2020

06:21AM EDT CytoDyn to Hold Conference Call on July 30 to Provide Updates on its Two COVID-19 Trials Benzinga

.dark-mode .BRnzgj{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .BRnzgj{ color: #333333; background-color: white; border: 2px solid #333333; }CYDYCYTODYN INCstock OTC

CYDY
CYTODYN INC
stock OTC